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Abstract
 
Mast cells (MCs) are immunoregulatory and inflammatory tissue cells preferentially located
around blood vessels. Since endothelial cells have been suggested to regulate MC functions, we
analyzed MC–endothelial cell interactions in vitro by performing coculture experiments with
purified human intestinal MCs and human umbilical vein endothelial cells (HUVECs). We
found that HUVECs provide signals allowing MCs to survive for at least 3 wk and to prolifer-
ate without addition of cytokines; otherwise all MCs died. HUVEC-dependent MC prolifera-
tion was more pronounced than that induced by stem cell factor (SCF), known to act as an
MC growth factor both in vitro and in vivo. After coculture with HUVECs, most MCs were
of the tryptase and chymase double-positive phenotype (MC
 
TC
 
). Transwell experiments sug-
gested that the HUVECs’ effects on MCs are not mediated by soluble factors. HUVEC-depen-
dent MC adhesion and proliferation were inhibited by neutralizing antibodies directed against
SCF and vascular cell adhesion molecule (VCAM)-1 expressed on HUVECs, and c-kit and
very late antigen 4 (VLA-4) on MCs. The data suggest that two mechanisms (membrane-
bound SCF/c-kit and VCAM-1/VLA-4) are involved in human MC–endothelial cell interac-
tions. In conclusion, our study provides evidence that endothelial cells regulate MC survival
and preferentially support human MC
 
TC
 
 development.
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Introduction
 
Human mast cells (MCs)
 
1
 
 are found predominantly in tis-
sues forming an interface between the host and external en-
vironment, such as skin, respiratory, and gastrointestinal
mucosa. MCs are also located in muscular organs such as
the heart and uterus, and around blood vessels in general,
which form a “barrier” between host tissue and blood
stream. Most MCs of the human body are located in gut
mucosa, which contains in their lamina propria 
 
z
 
2–3%
MCs. The density of MCs may be substantially increased at
sites of inflammation, wound healing, or tissue fibrosis (1–
4). MCs are recruited from poorly characterized bone mar-
row–derived progenitors circulating in blood and entering
the tissue where final maturation is achieved (5). We found
that after maturation, MCs may retain the capacity to pro-
liferate after cytokine stimulation, suggesting that MC den-
sity in tissue is dependent on local MC proliferation and
MC progenitor influx, which both could be regulated by
endothelial cells and other cell types (6).
In previous studies we presented methods for the isola-
tion and purification of human intestinal MCs and found
that these cells maintain in culture if stem cell factor (SCF)
has been added to the culture medium (7, 8). In the absence
of SCF, all MCs die within a few days, indicating that SCF
is a crucial and unique survival factor for human intestinal
MCs. SCF exists in a soluble and a membrane-bound form
generated by alternative splicing, and is produced by differ-
ent cell types, including endothelial cells expressing both
variants of SCF as well as c-kit, the SCF receptor (9–13).
We found that upon stimulation of endothelial cells with
the proinflammatory cytokines IL-1
 
a
 
 and TNF-
 
a
 
, SCF ex-
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 BrdU, 5-bromo-2
 
9
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T
 
, tryptase-positive MC(s);
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, tryptase and chymase double-positive MC(s); mSCF, membrane-
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adhesion molecule; VLA-4, very late antigen 4. 
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pression is upregulated, whereas that of c-kit is downregu-
lated (14). These data suggest that other cell types, e.g.
MCs, may be attracted by endothelial-derived SCF. Similar
findings were obtained for IL-1
 
a
 
 and IL-6, the expression
of which is induced in endothelial cells triggered by LPS
and further enhanced by IL-1
 
b
 
 and TNF-
 
a
 
 (15). Interest-
ingly, MCs could be involved in the regulation of SCF ex-
pression in endothelial cells, since we and others reported
that human MCs produce multiple cytokines, including IL-
1
 
b
 
 and TNF-
 
a
 
, particularly if the cells were stimulated
with bacterial products such as LPS or by IgE receptor
cross-linking (16). Furthermore, it was shown that MC
granules containing IL-1
 
b
 
, TNF-
 
a
 
, and other factors regu-
late IL-6 production in endothelial cells (17). These in vitro
findings together with the morphological observation that
MCs are typically located around blood vessels suggest a bi-
directional interaction between MCs and endothelial cells.
To further elucidate the mechanism of interaction be-
tween MCs and endothelial cells, we established a coculture
system using highly purified human intestinal MCs and hu-
man umbilical vein endothelial cells (HUVECs). We found
that MCs keep alive for many weeks in the absence of any
exogenous growth factor if cultured on an endothelial cell
layer. Endothelial cell–dependent MC survival is mediated
by SCF and adhesion molecules such as vascular cell adhe-
sion molecule (VCAM)-1. The data suggest that endothe-
lial cells play an important role in regulating not only MC
influx
 
 
 
but also MC development and function in tissue.
 
Materials and Methods
 
Reagents and Buffers.
 
The following cytokines were used for
cell culture and/or stimulation: SCF (25 ng/ml; provided by Dr.
L. Souza, Amgen, Thousand Oaks, CA), IL-1
 
b
 
 (10 ng/ml; Pep-
roTech), IL-4 (10 ng/ml; PeproTech), and TNF-
 
a
 
 (10 ng/ml;
PeproTech). The concentrations indicated above were found to
be maximally effective in our assays as determined in previous ex-
periments (6–8). MC culture medium is RPMI 1640 containing
10% heat-inactivated FCS (Biochrom), 25 mM Hepes (Sigma-
Aldrich), 2 mM 
 
l
 
-glutamine, 100 
 
m
 
g/ml streptomycin, 100 
 
m
 
g/
ml gentamycin, 100 U/ml penicillin, and 500 ng/ml fungizone
(all from Life Technologies).
 
Human MC Isolation and Purification.
 
Human intestinal MCs
were isolated from a surgical specimen (macroscopically normal
tissue) using a four-step enzymatic method as described previ-
ously (7, 8). MCs were partially purified up to 90% via selection
of c-kit–positive cells by magnetic cell separation (MACS™ sys-
tem; Miltenyi Biotec). The partially purified MCs were used for
MC–HUVEC or MC–fibroblast (FB) coculture or for MC mo-
noculture. These MC monocultures were supplemented with
growth factors such as IL-4 and/or SCF, or with HUVEC super-
natants/sonicates. Further purification of the MCs to 98–100%
was achieved by a 2-wk cell culture in MC culture medium sup-
plemented with 25 ng/ml SCF and 10 ng/ml IL-4 as described
(6, 8). The highly purified MC preparations were washed after 14 d
of culture, resuspended in new MC culture medium, and used for
stimulation with HUVEC supernatants or sonicates and for the
MC–HUVEC adhesion assay (see below).
 
Human FB Isolation and Purification.
 
Human intestinal FBs
were isolated from tissue dispersions obtained after enzymatic di-
 
gestion as described for human intestinal MCs (7). The cell sus-
pension containing 0.5–2% FBs was seeded into culture flasks and
cultured in MC culture medium. Contaminating nonadherent
cells were removed by changing the medium every 48–72 h. The
adherent FBs were sub-confluent after 5 d and were harvested af-
ter a 5-min incubation of the cells at 37
 
8
 
C with a buffer contain-
ing 0.25% trypsin and 0.02% EDTA (Biochrom). The FBs were
washed and seeded into new 80-cm
 
2
 
 flasks. The FB preparations
did not express CD31 surface marker (18) or von Willebrand fac-
tor (14; FACS
 
®
 
 analysis, data not shown), and thus were not con-
taminated by endothelial cells.
 
HUVEC Isolation and Culture.
 
HUVECs were isolated as de-
scribed in detail by Jaffe and coworkers (19). Freshly isolated cells
were cultured in HUVEC culture medium consisting of MC cul-
ture medium and M199 medium (Life Technologies) in a 1:2 ra-
tio. The culture flasks were coated with 0.1% gelatine (Sigma-
Aldrich). After 24 h, nonadherent cells were removed by changing
the culture medium and new medium was added to the adherent
cells. HUVECs were grown to confluence and were passaged
two to four times. Endothelial cell type was confirmed by FACS
 
®
 
analysis of von Willebrand factor and CD31, which were both
expressed by almost all cells (data not shown). HUVECs were
used for coculture with MCs or for the preparation of HUVEC
supernatants, HUVEC sonicates, and HUVEC RNA before and
after stimulation of the cells with 10 ng/ml IL-1
 
b
 
 or TNF-
 
a
 
 for
4 or 24 h.
 
MC–HUVEC Coculture Assay.
 
HUVECs obtained after the
second to fourth passage were cultured in MC culture medium in
24-well plates coated with 0.1% gelatine for at least 4 h to allow
adhesion on the surface of the plates. MCs purified by MACS™
were seeded onto subconfluent HUVEC monolayers with or
without separation of the two cell types using Transwell mem-
branes (0.4-
 
m
 
m pore size; Nunc). For some conditions MCs
were cocultured with HUVECs in the presence or absence of cy-
tokines (as described above) or neutralizing mAbs (anti–human
SCF, anti–human IL-3, and anti–human IL-3 receptor 
 
a
 
 chain
[R&D Systems]; anti-CD29, clone Lia1/2, anti-CD49d, clone
HP2/1, and anti-CD106, clone 1G11, all used at 5 
 
m
 
g/ml
[Coulter]). Total coculture time was up to 21 d. Every week, half
of the medium was changed and adherent and nonadherent MCs
and HUVECs were harvested using a cell scraper. All cells were
put on new HUVEC monolayers to avoid confluence and subse-
quent cell death of the HUVECs. MC numbers were determined
by cell counting. The MC countings were confirmed by deter-
mination of total cellular histamine content measured after cell
lysis. The MC–HUVEC cocultures were also used for adhesion
assay after a coculture time of 15 min to 6 h (see below).
 
MC–FB Coculture Assay.
 
FBs in the second to fourth passage
were cultured in MC culture medium for at least 4 h to allow ad-
herence. Subconfluent FBs were cocultured with MCs as de-
scribed above for MC–HUVEC cocultures.
 
RNA Isolation and Reverse Transcriptase PCR.
 
Total RNA was
isolated from 2 
 
3
 
 10
 
5
 
 human intestinal MCs (98–100% purity)
and from 2 
 
3
 
 10
 
5
 
 HUVECs (100% purity) using the RNeasy
Mini Kit (QIAGEN). Genomic DNA was removed by treating
200 ng of total RNA for 15 min at 37
 
8
 
C with 10 U/ml RNase-
free DNase (Promega). After denaturation for 10 min at 70
 
8
 
C,
cDNA was transcribed for 1 h at 37
 
8
 
C by adding Superscript™
reverse transcriptase (Life Technologies) and 20 pmol oligo dT
primers (Amersham Pharmacia Biotech). For each PCR 1/10 vol
of cDNA was used. PCR was performed in 35 cycles (60 s at
94
 
8
 
C, 80 s at 60
 
8
 
C, and 70 s at 72
 
8
 
C) using 2.5 U/ml Taq DNA
polymerase (Life Technologies). Intron-spanning sets of primers 
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were used to amplify cDNA specific for: glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) (sense: 5
 
9
 
-ACCACAGTCCAT-
GCCATCAC-3
 
9
 
; 20 mer and antisense: 5
 
9
 
-TCCACCACCCT-
GTTGCTGTA-3
 
9
 
; 20 mer, fragment size 452 bp), IL-4 (sense:
5
 
9
 
-CGGACACAAGTGCGATATCACC-3
 
9
 
, 22 mer and anti-
sense: 5
 
9
 
-CCAACGTACTCTGGTTGGCTTCC-3
 
9
 
; 23 mer,
fragment size 331 bp), soluble SCF (sSCF) (sense: 5
 
9
 
-GGGCTG-
GATCGCAGCGC-3
 
9
 
, 17 mer and antisense: 5
 
9
 
-CTCCA-
CAAGGTCATCCAC-3
 
9
 
; 18 mer, fragment size 276 bp), and
membrane-bound SCF (mSCF) (sense: 5
 
9
 
-CTTCAACAT-
TAAGTCCCTGAG-3
 
9
 
, 21 mer and antisense: 5
 
9
 
-GTCTAG-
GCTGGAGTCTCC-3
 
9
 
; 18 mer, fragment size for mSCF 359 bp
and for sSCF 275 bp). PCR products were visualized by ethidium
bromide staining after agarose gel electrophoresis.
 
MC Flow Cytometry.
 
MCs (98–100% purity) were washed
twice in PBS buffer containing 0.1% BSA and 0.1% NaN
 
3
 
. The
pellet was resuspended in the same buffer supplemented with 250
 
m
 
g/ml rabbit IgG (Dianova) for blocking Fc receptors. For each
condition, 1 
 
3
 
 10
 
5
 
 MCs were labeled with primary mAbs di-
rected against CD11a (clone 25.3.1; Coulter), CD11b (clone
BEAR1; Coulter), CD11c (clone B-ly6; Becton Dickinson),
CD15s (clone 2H5; Becton Dickinson), CD18 (clone MHM23;
Dako), CD29, CD31 (clone HC1/6; Southern Biotechnology
Associates, Inc.), CD33 (clone HIM3-4; Becton Dickinson),
CD43 (clone DFT1; Dianova), CD49a (clone HP2B6; Coulter),
CD49b (clone AK7; Becton Dickinson), CD49c (clone P1B5;
Becton Dickinson), CD49d, CD49e (clone SAM1; Coulter),
CD49f (clone GoH3; Becton Dickinson), CD50 (clone TU41;
Becton Dickinson), CD51 (clone 23C6; Southern Biotechnology
Associates, Inc.), CD54 (clone 84H10; Coulter), CD61 (clone
VI-PL2; Becton Dickinson), CD62E (clone 1.2B6; Southern
Biotechnology Associates, Inc.), CD62L (clone FMC46; South-
ern Biotechnology Associates, Inc.), CD62P (clone AK-4; Bec-
ton Dickinson), CD63 (clone H5C6, Becton Dickinson), CD102
(clone BMS109; Bender Systems), CD106, CD107a (clone
H4A3; Becton Dickinson), CD117 (clone YB5.B8; Becton
Dickinson), CD162 (clone KPL-1; Becton Dickinson), 
 
b
 
7 (clone
FIB504; Becton Dickinson), and anti–human SCF (reference 20;
clone 4B10). Appropriate isotype controls (mouse IgG1, IgG2a,
IgG2b, IgM, and rat IgG) were used (all from Southern Biotech-
nology Associates, Inc.). After an incubation time of 30 min at
4
 
8
 
C, cells were washed twice and stained for 30 min at 4
 
8
 
C with
the secondary Abs (FITC- or PE-conjugated goat anti–mouse
IgG1, IgG2a, IgG2b, IgM, or goat anti–rat IgG; all from South-
ern Biotechnology Associates, Inc.). FACS
 
®
 
 analysis was per-
formed using the FACSCalibur™ system and CELLQuest™ soft-
ware (Becton Dickinson).
 
HUVEC and FB Flow Cytometry.
 
Before staining, adherent
HUVECs or FBs were detached from the surface of the culture
flasks by treatment at 37
 
8
 
C with a solution containing 20 mmol/
liter Hepes, 150 mmol/liter sodium chloride, and 500 nmol/liter
EDTA in PBS, pH 7.2, for 20 min at 37
 
8
 
C. Remaining adherent
cells were harvested using a cell scraper and washed twice in
HUVEC or MC culture medium. For each condition, 2 
 
3
 
 10
 
5
 
HUVECs or FBs were stained with primary mAbs as described
above.
 
Adhesion Assay.
 
Human MCs were cocultured with HU-
VECs as described for the MC–HUVEC coculture assay. After a
variable coculture time (15 min to 6 h), nonadherent cells were
washed away and MC numbers of the remaining adherent cells
were determined by cell counting and cell differentiation of
smears stained with May-Grünwald/Giemsa (Merck). To inhibit
MC adhesion to HUVECs, different neutralizing mAbs were
 
added into the MC culture medium, such as anti–human SCF (5
 
m
 
g/ml; R&D Systems), anti-CD18, -CD29, -CD51, -CD54,
-CD106, -CD49d, -CD62P, -CD62L, -CD62E (all at 5 
 
m
 
g/ml;
the same Abs were used for flow cytometry), and anti–c-kit (ref-
erence 11; clone SR1, 1:100). Appropriate isotype controls (5
 
m
 
g/ml of mouse IgG1 and IgG2b, and goat IgG; Southern Bio-
technology Associates, Inc.) were included.
 
Scanning Electron Microscopy.
 
HUVECs (second to fourth pas-
sage) were cultured on 0.1% gelatine-coated glass cover slides for
at least 24–48 h to allow confluence of the cells. Then, MCs
were seeded onto the HUVEC monolayer and cocultured for
4 h. The adherent MCs were washed twice with pre-warmed
PBS buffer, fixed with Karnovsky’s fixative (2.5% glutaraldehyde
and 4% paraformaldehyde in 0.1 M sodium cacodylate, pH 7.4)
for 2 h, and rinsed overnight in 0.1% cacodylate buffer. The cells
were dehydrated in graded series of ethanol concentrations (30,
50, 70, and 90% each for 5 min two times and 100% each for 5 min
four times) and air-dried at room temperature. To detect the sur-
face structure of the cells, they were coated with gold-palladium
before analysis using a scanning electron microscope (model 505;
Phillips).
 
Immunocytochemistry.
 
Immunocytochemistry was performed
using mAbs against human tryptase (mouse IgG1, 230 ng/ml;
Chemicon) and human chymase (mouse IgG1, 100 ng/ml;
Chemicon) as primary Abs (overnight incubation at 4
 
8
 
C) and the
streptavidin-biotin detection system (Histostain-Plus kit; Zymed
Laboratories) as described (6–8). In all experiments, an appropri-
ate isotype control Ab was included (mouse IgG1, 230 ng/ml;
Southern Biotechnology Associates, Inc.). The number of
tryptase-positive (MC
 
T
 
) or tryptase and chymase double-positive
MCs (MC
 
TC
 
) was determined by analyzing 600 MCs.
 
SCF ELISA.
 
SCF was measured in supernatants of HUVEC
or FB monolayers (10
 
6
 
 cells/ml) incubated with or without 10
ng/ml TNF-
 
a
 
 for 4 h using Quantikine
 
®
 
 human SCF assay
(R&D Systems). The detection limit of the assay was 9.0 pg/ml.
 
Proliferation and Apoptosis Assays.
 
MCs that have been cul-
tured under different conditions (SCF alone, SCF and IL-4, co-
culture with HUVEC, and coculture with FB) were analyzed for
proliferation and apoptosis after 7 and 14 d of culture. MC pro-
liferation was assessed by quantification of cells incorporating
5-bromo-2
 
9
 
-deoxyuridine (BrdU) that was added to the cell culture
at 3 
 
m
 
g/ml for 3 d (during days 4–7 and days 11–14) following
the manufacturer’s instructions (Amersham Pharmacia Biotech).
Two negative controls were included (MCs not incubated with
BrdU and stained with anti-BrdU Ab, and MCs incubated with
BrdU but stained with an isotype control mouse IgG2a Ab)
yielding negative results (6). In addition, MC proliferation was
analyzed after 7 and 14 d of coculture with HUVECs or FBs by
counting cells staining positive after immunocytochemistry using
an Ab directed against the human nuclear cell proliferation anti-
gen Ki67 (mAb MIB-1 at 5 
 
m
 
g/ml; Dianova) and an isotype con-
trol Ab (mouse IgG1) as described (6). MC apoptosis was ana-
lyzed using the terminal deoxynucleotidyl transferase–mediated
dUTP nick end labeling in situ cell death detection kit for immu-
nocytochemistry (Boehringer). MC apoptosis was further exam-
ined by assessing MC binding of annexin V after incubation of
MCs for 15 min with 50 ng/ml annexin V–FITC using the
TACS™ Annexin V-FITC Apoptosis detection kit for FACS
 
®
 
analysis (R&D Systems).
 
Statistics.
 
Data were expressed as mean values 
 
6
 
 SD, if not
indicated otherwise. Statistical analysis was performed using the
two-tailed paired 
 
t
 
 test. A
 
 P 
 
, 
 
0.05 was considered to be statisti-
cally significant. 
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Results
 
Survival and Proliferation of MCs Cultured in the Presence of
HUVECs.
 
Confirming our recently published results, we
found that purified human intestinal MCs maintain in cul-
ture for several weeks if the culture medium was supple-
mented with SCF (Fig. 1). In the absence of SCF, all cells
died within 7 d (7). If the culture medium was supple-
mented with SCF and IL-4, a pronounced proliferation of
MCs was observed resulting in an enhanced MC number,
whereas IL-4 by itself failed to provide MC survival in cul-
ture (6). Most interestingly, Fig. 1 also shows that MCs
maintained in culture for up to 3 wk without any cytokine
supplementation if MCs were placed on an HUVEC
monolayer. These data strongly suggest that HUVECs sup-
port MC survival and proliferation, since the number of
MCs was higher after 21 d compared with the number at
culture start (152 
 
6
 
 20% MC recovery,
 
 n 5 13). The effect
of HUVECs on MC proliferation was higher than that of
SCF and more consistent than that of SCF and IL-4. In 4
out of 13 experiments, all MCs died in the presence of
SCF, and also in the presence of SCF and IL-4, but not if
cocultured with HUVECs. This suggests that the HUVEC-
dependent MC proliferation is not only mediated by SCF.
To elucidate the mechanism of HUVEC-dependent
MC proliferation, we compared the effects of HUVEC su-
pernatants and sonicates obtained from pure HUVECs cul-
tured for 21 d with that of HUVEC cocultures on MC
numbers. All HUVEC supernatants and sonicates failed to
provide MC survival if added to MC cultures, even if
HUVECs had been stimulated with IL-1b or TNF-a (both
at 10 ng/ml, n 5 4; data not shown). Separation of MCs from
HUVECs using Transwell membranes with a pore size of
0.4 mm almost abolished the proliferating effect of HUVECs
on MCs (Fig. 2 A). These data strongly suggest that
membrane-associated molecules rather than soluble factors
mediate the effect of HUVECs on MC survival and prolif-
eration. Fig. 2 B shows that MCs adhere to HUVECs and
that adhesion occurs in a time-dependent fashion. Already
15 min after the start of coculture at 378C, 10 6 1% of
MCs adhered on the cell surface of HUVECs (n 5 3). Af-
ter 2 h, 64 6 12% of MCs adhered to HUVECs as shown
in Fig. 3. The binding to HUVECs steadily increased with
time up to 98 6 2% MCs after 6 h. Once adhered to
HUVECs, MCs could not be removed from the surface of
the HUVECs by repeated washing.
We could confirm by light microscopy and scanning
electron microscopy that in MC–HUVEC coculture ex-
periments both cell types are in direct cell–cell contact (Fig.
3, A and B). In many cases, we detected mitotic MCs and
HUVECs if both cell types were adjacent (Fig. 3 C), fur-
ther suggesting that the interaction between the two cell
types induces proliferation of MCs and possibly also of
HUVECs. This could be confirmed by the incorporation
of BrdU in both MCs and HUVECs (Fig. 3, D and E).
Furthermore, we studied the MC subtypes that bound to
HUVECs and survived in the presence of HUVECs by im-
munocytochemistry (Fig. 3, F–I). If precultured MCs con-
taining z20–40% MCTC were cocultured with HUVECs
for 4 h, both MC subtypes bound to HUVECs (Fig. 3 F).
Analysis of MC subtypes after 14 d of coculture with
HUVECs  revealed a pronounced change of the MCTC/MCT
ratio of adherent MCs towards 85:15 (Fig. 3, G and H).
Cytokines Involved in MC–Endothelial Cell Interactions. It
is unlikely that IL-4 is involved in HUVEC-dependent
MC proliferation because we could show by reverse tran-
scriptase PCR that neither purified MCs nor HUVECs ex-
pressed IL-4 mRNA under these conditions, and we found
by FACS® analysis that both cell types separated after co-
culture using an EDTA buffer do not contain IL-4 protein
Figure 1. Coculture of human intestinal MCs with HUVECs. MCs
were cultured in medium supplemented with SCF (25 ng/ml), or with
SCF and IL-4 (10 ng/ml), or on a HUVEC monolayer. After 7, 14, and
21 d, respectively, MC numbers were counted and expressed in percent-
age of MC numbers at culture start. Each symbol represents one experi-
ment; the bars indicate mean values for each culture condition (n 5 13).
MC recovery after culture with HUVECs or with SCF and IL-4 was
compared with that after culture with SCF using the t test for paired sam-
ples (*P , 0.05, **P , 0.01, ***P , 0.001).
Figure 2. Effect of separation
of MCs from HUVECs and time
course of MC adhesion to en-
dothelial cells. (A) Effect of sepa-
ration of MCs from HUVECs
using Transwell (TW) plates
(0.4-mm pore size) on MC re-
covery. Means (6 SD) of three
experiments are shown. (B)
Time-dependent increase of per-
centage of MCs that adhered to
HUVECs. MCs were precul-
tured for 2 wk with 25 ng/ml
SCF and 10 ng/ml IL-4 before
coculture with HUVECs to en-
hance MC numbers and purity.
For details see Materials and
Methods. Means (6 SD) of three
experiments are shown.805 Mierke et al.
(data not shown). Moreover, the competitive IL-4 an-
tagonist RY at a maximally effective concentration of
500 nM failed to affect HUVEC-dependent MC survival
(6). IL-3 is also likely not involved in HUVEC-dependent
MC proliferation because we found that addition of neu-
tralizing mAbs directed against human IL-3 or IL-3 recep-
tor a chain at maximally effective concentrations to MC–
HUVEC cocultures did not affect MC proliferation (data
not shown).
On the other hand, SCF is obviously involved in the
MC–endothelial cell interaction because HUVEC-depen-
dent MC survival could be totally blocked by adding a
neutralizing anti-SCF Ab (Fig. 4 A). However, our obser-
vation that HUVECs were generally more effective than
SCF in providing MC survival suggests that other signals
may be involved. Such signals may enhance MC prolifera-
tion in the presence of SCF, but obviously fail to mediate
MC survival by themselves. HUVEC-stimulating cytokines
like IL-4, IL-1b, or TNF-a (all at 10 ng/ml) added to the
coculture system failed to enhance MC proliferation in
coculture experiments. In contrast, these cytokines strongly
reduced MC numbers (Fig. 4 B) without reducing MC
proliferation in MC monocultures supplemented with
SCF. Interestingly, neither the addition of SCF nor of SCF
and IL-4 to the coculture system significantly enhanced the
HUVEC-dependent MC proliferation (data not shown).
Fig. 5 A shows that MC counts are much lower if MCs
were cocultured for 21 d with FBs isolated from human in-
testinal tissue (33 6 11% MC recovery, n 5 3) compared
with coculture with HUVECs (174 6 30%). This could be
Figure 3. Direct cell–cell con-
tact between MCs and HUVECs.
(A) Light microscopy of MCs
and HUVECs cocultured for 14 d
(May-Grünwald/Giemsa stain).
(B) Scanning electron micros-
copy of MCs and HUVECs co-
cultured for 4 h showing a close
association between both cell
types. (C) Light microscopy of mi-
totic MCs (arrows) and HUVECs
cocultured for 14 d (May-Grün-
wald/Giemsa stain). (D and E)
BrdU incorporation shown by
immunocytochemistry in MCs
and HUVECs cocultured for
14 d. Cells were incubated with
3 mg/ml BrdU for 3 d before
harvesting and stained using (D)
anti-BrdU Ab or an (E) isotype
control mouse IgG2a Ab. (F) Im-
munocytochemistry using anti-
chymase mAb after 4 h of cocul-
ture. (G–I) Immunocytochemistry
using (G) antichymase mAb, (H)
antitryptase mAb, or an (I) isotype
control Ab (mouse IgG1, 230 ng/
ml) after 14 d of coculture.806 Endothelial Cells Regulate Mast Cell Functions
confirmed by studying MC proliferation using the BrdU
assay. Fig. 5 B shows that the portion of BrdU-incorporating
MCs was much higher in MC–HUVEC cocultures com-
pared with MC–FB cocultures, suggesting that HUVECs,
similar to the cytokines, enhance MC numbers by inducing
MC proliferation. Moreover, an enhancement of the pro-
liferation marker Ki67 was found in MCs cocultured for
14 d with HUVECs (16 6 1% Ki671 MCs after 7 d, 25 6
12% after 14 d, mean 6 SD, n 5 3) compared with MCs
cocultured with FBs (6 6 2 after 7 d, 6 6 3% after 14 d).
On the other hand, we have no evidence that the increased
MC numbers after 14 d of coculture with HUVECs are re-
lated to a decrease of MC apoptosis. By using the terminal
deoxynucleotidyl transferase–mediated dUTP nick end la-
beling assay in cytospins and the flow cytometric quantifi-
cation of annexin V–positive cells, we found no significant
differences in numbers of apoptotic MCs between the cul-
ture conditions (SCF, SCF and IL-4, HUVECs, and FBs;
data not shown).
Interestingly in this respect, we found that HUVECs do
not release detectable amounts of sSCF into supernatant
(,9 pg/106 cells). Even after stimulation with TNF-a (10
ng/ml for 4 h), HUVECs produced only small amounts of
sSCF (92 6 80 pg/106 cells, mean 6 SD, n 5 3) compared
with unstimulated FBs (1,608 6 156 pg/106 cells; Fig. 5
C). These results largely exclude the possibility that intesti-
nal FBs, which were possible contaminating cells in our
MC preparation, are significantly involved in MC–endo-
thelial cell interactions. Taken together, our data indicate
that mSCF is more effective than sSCF in providing MC
proliferation.
We could show by FACS® analysis that HUVECs ex-
pressed mSCF on their cell surface. The expression of
mSCF on HUVECs slightly increased after 4 h of coculture
with MCs (Fig. 6 A). Surprisingly, FBs expressed similar
levels of mSCF as HUVECs (Fig. 6 B). In contrast to pre-
vious data indicating mSCF expression in skin and cord
blood MCs (21), we found no SCF expression in human
intestinal MCs (Fig. 6 C), but high levels of c-kit (Fig. 6, D
and E). After 4 h of coculture with HUVECs, the intensity
Figure 4. Inhibitory effects of
neutralizing anti-SCF Ab and
proinflammatory cytokines on
the number of MCs cocultured
with HUVECs. (A) Effect of
neutralizing anti-SCF (aSCF)
Ab (5 mg/ml) on the number of
MCs cultured in the presence of
SCF or HUVECs. Means (6
SD) of three experiments are
shown. (B)  Purified MCs were
cocultured with HUVECs in the
presence of IL-1b, TNF-a, or
IL-4 (all at 10 ng/ml). Data are
expressed as percentage of
control (MCs cocultured with
HUVECs). Data (mean 6 SD)
of three experiments are shown.
Figure 5. Comparison of the
effects of HUVECs and FBs on
MC recovery. (A) Purified MCs
were cultured for 21 d in me-
dium supplemented with SCF or
SCF and IL-4. Alternatively,
MCs were cocultured with HU-
VECs or human intestinal FBs
for 21 d. MC recovery was de-
termined after 7, 14, and 21 d.
(B) Percentage of BrdU1 MC
cultured for 7 and 14 d with cy-
tokines (SCF, or SCF and IL-4)
or with cells (HUVECs or FBs).
(C) Measurement of sSCF in su-
pernatants of HUVECs (either
unstimulated or stimulated with
10 ng/ml TNF-a for 4 h) and of
FBs. Means (6 SD) of three ex-
periments are shown.
Figure 6. Expression of mSCF
on HUVECs, FBs, and MCs,
and expression of c-kit on MCs.
(A) Expression of mSCF on
HUVECs and (B) on human in-
testinal FBs with or without a
4-h coculture with MCs. (C) Ex-
pression of mSCF on MCs with
or without a 4-h coculture with
HUVECs. (D) Regulation of
c-kit expression on the cell surface
of MCs after a 4-h culture time
with or without HUVECs. (E)
Same as D, but HUVECs were
replaced by human intestinal
FBs. One representative experi-
ment out of three is shown. In all
histograms the leftmost peak
(dotted line) represents the iso-
type control.807 Mierke et al.
of c-kit expression on MCs was significantly increased (Fig.
6 D). In contrast, coculture of MCs with FBs clearly re-
duced c-kit expression on MCs (Fig. 6 E).
Adhesion Proteins Involved in MC–Endothelial Cell Interac-
tions. We found by FACS® analysis that human intestinal
MCs and FBs as well as HUVECs express a variety of adhe-
sion molecules, summarized in Table I. With regard to se-
lected adhesion molecules, the number of positive cells and
mean relative fluorescence of stained cells were slightly
modulated by coculture of the cells with other cell types
(data not shown). The expressions of VCAM-1 and intra-
cellular adhesion molecule (ICAM)-1 on HUVECs and FBs
were enhanced after 4 h of coculture with MCs (Fig. 7 A).
VCAM-1 expression on HUVECs cocultured with MCs
increased in a time-dependent fashion and reached the
maximum after 4 h. The upregulation of VCAM-1 was
stable for up to 48 h (Fig. 7 B). MCs also increased E-selec-
tin expression on HUVECs, whereas no E-selectin expres-
Table I. FACS® Analysis of Adhesion Molecules on Human Intestinal MCs, Human Intestinal FBs, and HUVECs
MCs HUVECs FBs
Ab Target Ligands (examples) % pc Dmf % pc Dmf % pc Dmf
Selectins CD62E E-selectin sLewis x, PSGL-1 25 3 30 7 0 0
CD62L L-selectin sLewis x, PSGL-1 94 19 0 0 0 0
CD62P P-selectin sLewis x, PSGL-1 28 2 0 0 0 0
Mucins CD162 PSGL-1 P- and L-selectin 100 734 33 5 75 33
CD15s sLewis x L-, E-, P-selectin 99 773 100 542 62 313
CD43 Leucosialin ICAM-1 100 436 0 0 0 0
b1 integrins CD29 b1 – 100 273 100 2,804 97 2,241
CD49a a1 (VLA-1) Laminin 0 0 10 1 0 3
CD49b a2 (VLA-2) Collagen 97 23 100 860 100 392
CD49c a3 (VLA-3) Fibronectin 74 12 100 151 100 180
CD49d a4 (VLA-4) VCAM-1 100 106 100 57 98 227
CD49e a5 (VLA-5) Fibronectin 99 6 100 326 100 435
CD49f a6 (VLA-6) Laminin 0 0 91 149 0 0
b2 integrins CD18 b2 –8 8 2 4 0 0 0 0
CD11a LFA-1 ICAM-1, -2, -3 92 31 0 0 ND ND
CD11b Mac-1 ICAM-1, -2, -3 17 1 0 0 ND ND
CD11c P150, 95 C3bi, fibrinogen 55 4 0 0 ND ND
b3 integrins CD61 b3 – 100 56 99 157 72 322
CD51 av PECAM-1, vitronectin 66 13 97 32 62 37
b7 integrins – b7 – 60 22 23 4 30 24
CD107a a4b7 (Act-1) VCAM-1, fibronectin 36 5 58 15 50 25
Immunoglobulin CD54 ICAM-1 LFA-1,  Mac-1 99 104 59 16 89 470
superfamily CD102 ICAM-2 LFA-1, Mac-1 33 4 100 1,244 17 6
CD50 ICAM-3 LFA-1 42 4 0 0 0 0
CD106 VCAM-1 VLA-4, LPAM-1 0 0 10 1 20 5
CD31 PECAM-1 PECAM-1, LFA-1 43 5 100 957 0 0
CD33 – – 97 61 0 0 ND ND
CD63 – – 100 81 100 70 100 501
FACS® results are expressed as percentage of positive cells (% pc) and difference in mean relative fluorescence between stained cells and isotype control
(Dmf). One representative experiment (out of at least three) is shown. PECAM, platelet-endothelial cell adhesion molecule.808 Endothelial Cells Regulate Mast Cell Functions
sion was detectable on FBs (Fig. 7 A). FACS® analysis re-
vealed that the inhibitory effect of TNF-a and IL-1b
shown in Fig. 4 B is not related to the expression of
VCAM-1 on HUVECs or VLA-4 on MCs (data not
shown). Using the adhesion assay described previously, we
tested different neutralizing Abs directed against adhesion
molecules for their ability to inhibit MC adhesion to
HUVECs and MC proliferation in coculture with HUVECs
(Table II). MC adhesion to HUVECs was clearly reduced
by the addition of Abs against CD29, CD49d, CD106, and
CD62E. The simultaneous addition of mAbs against
VCAM-1 and the two components of VLA-4 resulted in a
reduction of MC adhesion to 26 6 2% of the control (P ,
0.001). Anti-SCF and anti–c-kit mAb also reduced signifi-
cantly the adhesion of MCs to HUVECs (21 6 5 and 23 6
7%, P , 0.001), suggesting that at least two mechanisms
are involved in MC–HUVEC interactions (SCF/c-kit and
VCAM-1/VLA-4). The combination of all five neutraliz-
ing mAbs further reduced the adhesion of MCs to HUVECs
(15 6 3%, P , 0.001). The mAbs directed against adhesion
molecules not only inhibited MC adhesion towards HUVECs
but also HUVEC-dependent MC survival and prolifera-
tion. After 7 d of coculture, MC recovery was not yet
changed significantly by addition of each neutralizing mAb
or of all three mAbs together. However, after 14 d MC re-
covery was slightly reduced by each mAb, and a significant
reduction of MC recovery (percentage of control, MC
coculture with HUVEC and appropriate isotype controls)
was observed if all three mAbs were administered simulta-
neously (17 6 9%, n 5 3; P , 0.05, Table II).
Discussion
In previous studies we and others found that isolated hu-
man MCs maintain in culture only if either the growth fac-
tor SCF was added or the cells were cocultured with
mouse FB cell lines that express SCF (7, 22, 23). In this
study we report for the first time that isolated human intes-
tinal MCs survive for at least 21 d and proliferate in cocul-
ture with HUVECs without addition of any cytokines.
Our preliminary results indicate that similar observations
can be made if HUVECs are replaced by human endothe-
lial cells isolated from intestinal tissue (data not shown),
suggesting that the findings are not restricted to HUVECs.
Figure 7. Regulation of
VCAM-1, E-selectin, and
ICAM-1 expression on HUVECs
and FBs in coculture with MCs.
(A) Expression of VCAM-1,
E-selectin, and ICAM-1 on
HUVECs (left panels) and hu-
man intestinal FBs (right panels)
without (gray line) or with a 4-h
coculture with MCs (black line).
(B) Time-dependent expression
of VCAM-1 on HUVECs (bars)
and FBs (squares) after coculture with MCs. VCAM-1 expression on
HUVECs and FBs is expressed as the difference between the geometric
mean fluorescence of VCAM-1 staining and isotype control condition
(Dmf). Basal VCAM-1 expression on HUVECs and on FBs not cocul-
tured with MCs is shown in the leftmost bar (basal) or, respectively, left-
most square. One representative experiment out of three is shown.
Table II. Effect of Neutralizing Abs on MC Adhesion to 
HUVECs and MC Recovery in Coculture with HUVECs
Ab Target
Adhesion
(percentage 
of control)
MC 
recovery
(percentage 
of control)
Anti-CD29 b1 integrin 35 6 5 74 6 34
Anti-CD49d a4 integrin 41 6 9 86 6 23
Anti-CD106 VCAM-1 39 6 9 54 6 42
Anti-SCF SCF 21 6 50
Anti–c-kit c-kit 23 6 70
Anti-SCF 1 Anti–c-kit – 21 6 70
Anti-CD29 1 Anti-CD49d
1 Anti-CD106 – 26 6 2 17 6 9
Anti-CD29 1 Anti-CD49d
1 Anti-CD106 1 Anti-SCF – 19 6 40
Anti-CD29 1 Anti-CD49d
1 Anti-CD106 1 Anti-SCF 
1 Anti–c-kit – 15 6 30
Anti-CD18 b2 integrin 96 6 3N D
Anti-CD61 b3 integrin 95 6 2N D
Anti-CD54 ICAM-1 70 6 7N D
Anti-CD62L L-selectin 78 6 13 ND
Anti-CD62E E-selectin 52 6 11 ND
Anti-CD62P P-selectin 85 6 4N D
Means 6 SD are shown, n = 3. Adhesion was determined after 4 h and
MC recovery after 14 d. Controls were carried out with appropriate
isotypes.809 Mierke et al.
According to our data, the effect of HUVECs on MCs re-
sulting in increased MC numbers is because of enhanced
MC proliferation and not because of decreased MC apop-
tosis. Surprisingly, human intestinal FBs were less potent in
promoting MC survival and proliferation compared with
endothelial cells. These data suggest that endothelial cells
may be of particular relevance for the regulation of MCs in
tissue in at least two means. Endothelial cells are clearly in-
volved in the regulation of MC progenitor recruitment
from the blood stream (24), an issue that was not addressed
by these studies, and endothelial cells may regulate tissue
MC density by modulating MC survival and proliferation,
as indicated by our data.
Our results clearly indicate that membrane-bound mole-
cules rather than soluble factors are mediating the effects of
endothelial cells on MC survival and proliferation. Accord-
ing to our results, at least two molecular mechanisms are
supposed to play a role, the SCF–c-kit and the VCAM-1–
VLA-4 interaction, whereas IL-4 is obviously not involved.
It is known from previous studies that HUVECs and en-
dothelial cells of other origins, similar to FBs, express sSCF
and mSCF (12, 13). We confirm these findings by showing
that mSCF is expressed by HUVECs as well as intestinal FBs,
and that FBs produce 17 times more sSCF than HUVECs.
Inhibition studies using neutralizing Abs directed against
SCF confirm the crucial role of mSCF in mediating endo-
thelial cell–dependent MC survival and proliferation. The
effects of HUVECs on MC survival and proliferation could
by totally blocked by anti-SCF Ab. However, several func-
tional studies indicate that SCF, which binds to c-kit ex-
pressed on MCs, may not be the only factor involved in
this MC–endothelial cell interaction. For example, MC
numbers were clearly higher in MC–HUVEC cocultures
compared with MC cultures supplemented with SCF.
Moreover, in 4 out of 13 experiments MCs died in the
presence of sSCF, but not if co-cultured with HUVECs.
The higher potency of HUVECs compared with SCF re-
garding MC survival is not related to IL-4, which was pre-
viously found to be capable of enhancing SCF effects (6),
since neither MCs nor HUVECs expressed IL-4 in the
coculture assay and HUVEC-dependent MC survival and
proliferation was not affected by the addition of the com-
petitive IL-4 inhibitor RY. Apart from IL-4, other cyto-
kines known to have synergistic effects with SCF on MC
proliferation may be involved in MC–endothelial cell in-
teractions. However, at least for IL-3 and IL-5, we could
largely exclude this possibility by using neutralizing Abs
against IL-3 or its receptor, and by showing that IL-5 does
not enhance SCF-dependent MC proliferation (our un-
published results). Thus, two other explanations may be
envisioned. Either “solid phase SCF,” such as mSCF, is
more potent than sSCF with regard to MC proliferation,
and/or yet unknown cofactors are involved in the SCF-
dependent effects of endothelial cells on MCs. To address
the second hypothesis, we studied several adhesion factors
expressed on MCs or HUVECs because adhesion factors
are candidates within membrane-bound factors that may
modulate MC–endothelial interactions (25).
Human MCs of different origins express high levels of a4
and b1 integrin chains assembling to the VLA-4 complex
that is also expressed on lymphocytes, eosinophils, and
monocytes (26–28). VLA-4 binds to VCAM-1 expressed
on endothelial cells and is involved in mediating adhesion
of eosinophils, lymphocytes, and monocytes to the endo-
thelium (29, 30). Similar results were obtained for the rat
mucosal-type MC lines RBL-1 and RCMC-1 that express
VLA-4 and bind to VCAM-1, suggesting a mechanism for
MC accumulation at sites of inflammation (31). The high
expression of a4 and b1 integrin chains on human intestinal
MCs and the upregulation of VCAM-1 expression on
HUVECs we found after coculture with MCs suggest a
functional significance of this pathway. The facts that MC
adhesion to the cell surface of HUVECs and that HUVEC-
dependent MC proliferation was clearly inhibited by the
addition of neutralizing mAbs directed against a4, b1,
and VCAM-1 strongly support the notion that MCs and
HUVECs interact through the VLA-4 complex and
VCAM-1. This interaction may cause an enhancement of
MC proliferation mediated by the binding of endothelial
mSCF to c-kit on MCs. A synergism between the VCAM-
1/VLA-4 and the mSCF/c-kit pathway may be anticipated
and provides an explanation for the observation that HUVECs
forming a direct cell–cell contact with MCs are more effec-
tive in mediating MC proliferation than soluble cytokines
such as SCF.
In previous studies, FBs were found to provide MC sur-
vival in vitro (22, 23, 32, 33), whereas endothelial cells
have not been examined in this respect. Both human and
rodent MCs survived for different time periods (average 1–8
wk) if cultured on rodent FB cell lines (mostly 3T3 FBs
derived from Balb/c mice or Swiss albino mice). The ca-
pacity of FB supernatants to provide MC survival was de-
pendent on the amount of sSCF released by the different
FB types (32). Accordingly, the effects of human intestinal
FBs on MCs were comparable to those induced by SCF,
but were clearly weaker than those of endothelial cells, de-
spite the fact that FBs not only release sSCF but also express
mSCF. Thus, the effect of FBs is most likely due to their
release of SCF rather than their expression of mSCF. It re-
mains unclear why human intestinal FBs are less potent in
promoting MC survival and proliferation compared with
endothelial cells, although they express both mSCF and
VCAM-1 in similar amounts as HUVECs. This discrep-
ancy may be related to our observation that HUVECs en-
hanced c-kit expression in MCs, whereas FBs downregu-
lated it. Previous studies reported a downregulation of c-kit
in human lung MCs and MC lines by SCF (34), which
may be prevented by yet unknown endothelial factors. Al-
ternatively, human intestinal FBs may produce factors that
downregulate MC responsiveness towards mSCF and
VCAM-1. This hypothesis is supported by our finding that
a 4-h challenge of MCs with SCF or with Fce receptor Ab,
ionomycin, and cytokines such as IL-1b, IL-4, and TNF-a
decreases c-kit expression on MCs (our unpublished re-
sults). Another possibility may be that HUVECs, but not
FBs, express cofactors enhancing the effect mediated by810 Endothelial Cells Regulate Mast Cell Functions
mSCF and VCAM-1. Such a cofactor may be E-selectin,
which is expressed on HUVECs but not on FBs. Interest-
ingly, the number of E-selectin–positive HUVECs is in-
creased after coculture with MCs (from 30 to 61%), and
the addition of anti-CD62E neutralizing mAb to the cocul-
ture clearly reduced MC adhesion to HUVECs, suggesting
a functional significance of E-selectin in MC–HUVEC in-
teractions.
Our finding that endothelial cells regulate human intesti-
nal MC functions such as survival, proliferation, and possi-
bly other functions not yet examined such as mediator re-
lease may have several clinical implications. Endothelial
cells, in contrast to soluble growth factors, selectively sup-
port the survival and growth of so-called “connective tis-
sue–type MCs” containing tryptase and chymase (MCTC).
Before coculture, only zone third of the MCs are MCTC
(6), but after 14 d of coculture with HUVECs, more than
four fifths of the MCs are of the MCTC subtype, indicating
that HUVECs rather selectively promote proliferation of
MCTC or induce a change in MC phenotype. The fact that
endothelial cells preferentially support connective tissue–
type MCs known to be involved in wound healing, tissue
remodeling, and fibrosis suggests a function of MCs and
endothelial cells in such processes. In contrast, sSCF and
IL-4 support “mucosal-type MCs” (MCT) thought to me-
diate inflammatory processes such as allergic reactions or
inflammatory bowel disease (6, 7). Our observation that
proinflammatory endothelial cell agonists such as IL-1b,
TNF-a, and IL-4 reduced MC numbers in our coculture
system suggests that endothelial cell–dependent MCTC reg-
ulation is of particular importance during noninflammatory
or postinflammatory conditions.
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